ADL/Metabolomic Technologies' PolypDx Urine-Based Diagnostic Test
Atlantic Diagnostic Laboratories has launched Metabolomic Technologies' PolypDx, a non-invasive urine-based test for detection of adenomatous polyps, the precursor to colorectal cancer. PolypDx only requires a small urine sample for analysis. In a Canadian clinical trial the test demonstrated significantly higher sensitivity than a current fecal-based screening test to detect adenomatous polyps, the company said.
PolypDX is the flagship product of Metabolomic Technologies, a privately held Canadian company that has given ADL exclusive licensing and distribution rights to bring the test to the US market.